618061-76-0 Usage
Description
(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is a complex organic compound with a unique chemical structure. It is an impurity of Afatinib, a quinazoline derivative that has been developed for the treatment of various types of cancer and diseases affecting the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is characterized by its specific stereochemistry, with the (S)-configuration indicating the spatial arrangement of its atoms.
Uses
Used in Pharmaceutical Industry:
(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is used as an impurity in the synthesis and production of Afatinib. It plays a crucial role in the development and manufacturing process of this anticancer drug, ensuring the purity and efficacy of the final product.
Used in Cancer Treatment:
As an impurity of Afatinib, (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate contributes to the overall therapeutic effect of the drug. Afatinib is used for treating various types of cancer, including those affecting the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate's unique structure allows it to target specific cellular pathways and inhibit the growth and proliferation of cancer cells.
Used in Research and Development:
(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is also used in research and development for the discovery of new drugs and therapies. Its unique chemical properties and interactions with biological systems make it a valuable tool for studying the mechanisms of action and potential applications of quinazoline derivatives in medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 618061-76-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,8,0,6 and 1 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 618061-76:
(8*6)+(7*1)+(6*8)+(5*0)+(4*6)+(3*1)+(2*7)+(1*6)=150
150 % 10 = 0
So 618061-76-0 is a valid CAS Registry Number.
618061-76-0Relevant articles and documents
Compound, and preparation method and application thereof
-
Paragraph 0052-0057, (2017/08/30)
The invention relates to a compound, and a preparation method and application thereof. Specifically, the compound is as shown in a formula 1 which is described in the specification. The invention also provides the preparation method for the compound as shown in the formula 1. The preparation method comprises a step of contacting N-[4-[(3-chloro-4-fluorophenyl)amino]-7[[(3S)-tetrahydro-3-furyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butyleneamide with an alkaline aqueous solution in an organic solvent so as to obtain the compound as shown in the formula 1. The preparation method is simple to operate; a white powder product can be obtained through direct filtering after post-treatment; and the prepared compound has high purity, as high as 99% or above, and can be directly used as an impurity control substance for research on the quality of an afatinib bulk drug.
PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES
-
Page/Page column 22-23, (2008/06/13)
The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.
Process for preparing amino crotonyl compounds
-
Page/Page column 6, (2010/02/11)
The invention relates to an improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylam ino)-1 -oxo-2-buten-1 -yl]am ino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1 -oxo-2-buten-1 -yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.
